These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 30782607)

  • 41. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
    Zhao Y; Shen S; Guo J; Chen H; Greenblatt DY; Kleeff J; Liao Q; Chen G; Friess H; Leung PS
    J Surg Res; 2006 Dec; 136(2):325-35. PubMed ID: 17054996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer.
    Liao YN; Huang PQ; Pan H; Gai YZ; Zhan YF; Li SX; Nie HZ
    FASEB J; 2024 May; 38(10):e23705. PubMed ID: 38805171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts.
    Konaté MM; Krushkal J; Li MC; Chen L; Kotliarov Y; Palmisano A; Pauly R; Xie Q; Williams PM; McShane LM; Zhao Y
    J Transl Med; 2024 Aug; 22(1):733. PubMed ID: 39103840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
    Harikumar KB; Kunnumakkara AB; Sethi G; Diagaradjane P; Anand P; Pandey MK; Gelovani J; Krishnan S; Guha S; Aggarwal BB
    Int J Cancer; 2010 Jul; 127(2):257-68. PubMed ID: 19908231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
    Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A
    Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells.
    Gong XG; Lv YF; Li XQ; Xu FG; Ma QY
    Biol Pharm Bull; 2010; 33(8):1261-7. PubMed ID: 20686216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.
    Liau SS; Ashley SW; Whang EE
    J Gastrointest Surg; 2006 Nov; 10(9):1254-62; discussion 1263. PubMed ID: 17114012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance.
    Dalin S; Sullivan MR; Lau AN; Grauman-Boss B; Mueller HS; Kreidl E; Fenoglio S; Luengo A; Lees JA; Vander Heiden MG; Lauffenburger DA; Hemann MT
    Cancer Res; 2019 Nov; 79(22):5723-5733. PubMed ID: 31484670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer.
    Yang Z; Chen F; Wei D; Chen F; Jiang H; Qin S
    BMC Cancer; 2024 Feb; 24(1):268. PubMed ID: 38408959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
    J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
    Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
    Gordon ER; Wright CA; James M; Cooper SJ
    BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
    J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IFN‑γ induces apoptosis in gemcitabine‑resistant pancreatic cancer cells.
    Kong X; Cheng D; Xu X; Zhang Y; Li X; Pan W
    Mol Med Rep; 2024 May; 29(5):. PubMed ID: 38488034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
    Simon PO; McDunn JE; Kashiwagi H; Chang K; Goedegebuure PS; Hotchkiss RS; Hawkins WG
    Int J Cancer; 2009 Aug; 125(4):942-51. PubMed ID: 19405118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.
    Wang SJ; Gao Y; Chen H; Kong R; Jiang HC; Pan SH; Xue DB; Bai XW; Sun B
    Cancer Lett; 2010 Jul; 293(1):99-108. PubMed ID: 20137856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
    Uwagawa T; Chiao PJ; Gocho T; Hirohara S; Misawa T; Yanaga K
    Anticancer Res; 2009 Aug; 29(8):3173-8. PubMed ID: 19661331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
    Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
    Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol.
    Zhou L; Qi L; Jiang L; Zhou P; Ma J; Xu X; Li P
    AAPS J; 2014 Mar; 16(2):246-57. PubMed ID: 24424498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
    Wei SH; Dong K; Lin F; Wang X; Li B; Shen JJ; Zhang Q; Wang R; Zhang HZ
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1055-64. PubMed ID: 18297287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.